Cyfuse Biomedical KK (TSE:4892) EBIT: 円-454.15 Mil (TTM As of Dec. 2025)


TSE:4892 Cyfuse Biomedical KK TSE:4892
53 GF Score
Price 円552.00
GF Value 円2,179.63
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK EBIT?

Cyfuse Biomedical KK TSE:4892 +2.99% 53 EBIT is 円-454.15 Mil as of Dec. 2025. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,179.63 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cyfuse Biomedical KK's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was 円0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-454.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cyfuse Biomedical KK's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Cyfuse Biomedical KK's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cyfuse Biomedical KK's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -14.16%.

Cyfuse Biomedical KK  (TSE:4892) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cyfuse Biomedical KK's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (978.368 + 1064.587)/ 2 )
=0/1021.4775
=0.00 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4299.728 - 45.499 - ( 3742.279 - max(0, 670.75 - 3946.611+3742.279))
=978.368

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4266.026 - 133.038 - ( 3726.535 - max(0, 866.063 - 3934.464+3726.535))
=1064.587

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Cyfuse Biomedical KK's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (211.049 + max(-27.805, 0)) + (203.31 + max(-28.541, 0)) )/ 2 )
=0/( ( 211.049 + 203.31 )/ 2 )
=0/207.1795
=0.00 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.983 + 59.33 + 104.966) - (45.499 + 0 + 150.585)
=-27.805

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.464 + 88.739 + 73.655) - (133.038 + 0 + 63.361)
=-28.541

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cyfuse Biomedical KK's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-454.154/3208.100
=-14.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK EBIT Related Terms

Cyfuse Biomedical KK EBIT Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK EBIT Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 150.15 -444.02 -576.41 -860.23 -747.02

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.54 -236.28 0.00 0.00 -217.87

TSE:4892 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyfuse Biomedical KK EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's EV-to-EBIT falls into.


TSE:4892
53GF Score
Cyfuse Biomedical KK TSE:4892
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-454.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-454.15 Mil mean?
Cyfuse Biomedical KK (TSE:4892) has a EBIT of 円-454.15 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyfuse Biomedical KK.
Is Cyfuse Biomedical KK's EBIT too high?
Cyfuse Biomedical KK's current EBIT is 円-454.15 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's EBIT compare to ZTS and UTHR?
Cyfuse Biomedical KK's EBIT of 円-454.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyfuse Biomedical KK. Cyfuse Biomedical KK's current EBIT is 円-454.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current EBIT is 円-454.15 Mil. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current EBIT is 円-454.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • EBIT: 円-454.15 Mil
  • GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score

Get the complete analysis for TSE:4892

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円552.00
Price
円2,179.63
GF Value